Feature | AHA | November 20, 2020| Dave Fornell, Editor

American Heart Association 2020 Late-breaking Trial Presentations 

Listing of all the late-breaking science sessions at AHA 2020

The American Heart Association, AHA, late-breaking sessions, trials, studies. #AHA #AHA20 #AHA2020

Here is a list of the American Heart Association (AHA) late-breaking clinical trial presentations at the 2020 Virtual AHA meeting Nov 13-17, 2020. Find a complete listing of all AHA 2020 sessions.

Heart Failure and Atrial Fibrillation: Vitamins, Minerals, Nutrients, and More

Fri, Nov. 13,  10:30 - 11:30 a.m. CST
   • State of the Science: The 4 Pillars of Heart Failure Therapy. Presented by Marc Pfeffer, M.D.

   • Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: The Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) Trial. Presented by John Teerlink, M.D.

   • Ferric Carboxymaltose in Iron Deficient Patients Admitted for Acute Heart Failure (AFFIRM-AHF). Presented by Piotr Ponikowski, Ph.D.

   • The Vital Rhythm Trial: Omega-3 Fatty Acid and Vitamin D Supplementation in the Primary Prevention of Atrial Fibrillation (VITAL-Rhythm). Presented by Christine Albert, M.D.

Bending the Curve for CV Disease - Precision or PolyPill?

Fri, Nov. 13  Noon - 1 p.m. CST
   • State of the Science: Global CVD Prevention. Presented by Dorairaj Prabhakaran, M.D.

   • A Polypill for Primary Prevention of Cardiovascular Disease in Intermediate Risk People: Results of the International POLYCAP Study (TIPS)-3. Presented by Prem Pais, M.D.

   • Aspirin Alone and in Combination With a Polypill in Cardiovascular Disease Primary Prevention: Results From the International POLYCAP Study (TIPS)-3. Presented by Salim Yusuf, MBBS.

   • Prevalence and Prediction of Coronary Artery Disease in the General Population - Results From the Swedish Cardiopulmonary Bioimage Study (SCAPIS). Presented by Göran Bergström. 

Current Challenges in Coronary and Valve Disease

Sat, Nov. 14, Noon - 1 p.m. CS
   • Ticagrelor versus Clopidogrel in Elective Percutaneous Coronary Intervention: The ALPHEUS Trial. Presented by Johanne Silvain, M.D.

   • Coronary OCT and Cardiac MRI to Determine Underlying Causes of MINOCA in Women (HARP-MINOCA). Presented by Harmony Reynolds, M.D.

   • Rivaroxaban versus Warfarin in Patients With Bioprosthetic Mitral Valves and Atrial Fibrillation or Flutter: Primary Results From the RIVER Randomized Trial. Presented by Otavio Berwanger, M.D.
 

Fish Oil, Fancy Drugs, and Frustrations in Lipid Management

Sun, Nov. 15, 9 - 10 a.m. CST
   • STRENGTH Trial: Cardiovascular Outcomes With Omega-3 Carboxylic Acids (Epanova) in Patients With High Vascular Risk and Atherogenic Dyslipidemia. Presented by A. Lincoff, M.D.

   • Effects of N-3 Fatty Acid Supplements on Clinical Outcome After Myocardial Infarction in The Elderly: Results of the OMEMI Trial. Presented by Are Annesoenn Kalstad, M.D.

   • A Three-arm N-of-1 Trial With Statin, Placebo and Tablet Free Periods, to Verify Side Effects and Identify Their Cause: The SAMSON Trial. Presented by James Philip Howard, M.D.

   • The Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia. Presented by Robert S. Rosenson, M.D.
 

Stents, Valves and Clots

Sun, Nov. 15, 7:15 - 8:30 p.m. CST
   • A Prospective Multicenter Randomized Controlled Trial Assessing the Safety and Efficacy of the BuMA Supreme Biodegradable Drug Coated Coronary Stent System in Patients With Stable or Non-ST Elevation Acute Coronary Syndromes: Primary Endpoint Results of the PIONEER III Trial. Presented by Alexandra Lansky, M.D.

   • One Month Dual Antipletelet Therapy Followed by Aspirin Monotherapy After Drug Eluting Stent Implantation. Presented by Myeong-Ki Hong, M.D.
 

To Screen or Not to Screen, and then What? Studies of Detection and Treatment of AF

Mon, Nov. 16, 9 - 10 a.m. CST
   • State of the Science: Screening for AF. Presented by Rod Passman, M.D.

   • Enhanced Monitoring for Atrial Fibrillation Following Cardiac Surgery: Primary Results of the SEARCH-AF Cardiolink Randomized Trial. Presented by Subodh Verma, M.D.

   • Screening for Atrial Fibrillation in Older Adults at Primary Care Visits Using Single Lead Electrocardiograms: The VITAL-AF Trial. Presented Steven A. Lubitz, M.D.

   • 3-year Clinical Outcomes in a Nationwide, Randomized, Pragmatic Clinical Trial of Atrial Fibrillation Screening - Mhealth Screening to Prevent Strokes (MSTOPS) using a wearable cardiac monitor. Presented by Steven R Steinhubl, M.D.

   • Early Invasive Intervention for Atrial Fibrillation With Cryoablation (EARLY-AF). Presented by Jason Andrade.
 

Randomized Trials – Brain, Kidney, and Heart

Mon, Nov. 16, 7 - 8:30 p.m. CST
   • Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes (FIDELIO-DKD). Presented by Gerasimos Filippatos, M.D.

   • Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Tia of Atherosclerotic Origin (THALES). Presented by Pierre Amarenco, M.D.

   • RHAPSODY: Rilonacept an IL-1α and IL-1β Trap Resolves Pericarditis Episodes and Reduces Risk of Recurrence in a Phase 3 Trial of Patients With Recurrent Pericarditis. Presented by Allan Klein, M.D.

   • Rapid Assessment of Potential Ischaemic Heart Disease With CTCA: The Rapid-CTCA Trial. A Randomised Trial of CTCA in the Evaluation, Intervention and Outcome Of adults With Suspected or Confirmed Acute Coronary Syndrome Presenting to the Emergency Department (RAPID-CTCA). Presented by Alasdair Gray, M.D.

   • SOLOIST-WHF: Sotagliflozin in Diabetes Patients with Recent Worsening Heart Failure. Presented by Deepak Bhatt, M.D.

   • SCORED: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. Presented by Deepak Bhatt, M.D.

AHA Goes Viral: COVID-19, Influenza Vaccines, and Cardiovascular Disease

Tue, Nov. 17, 9 - 10 a.m. CST
   • The AHA COVID-19 Cardiovascular Disease Registry: Design, Implementation, and Initial Results. Presented by James A. De Lemos, M.D.

   • Racial and Ethnic Differences in Treatment and Outcomes for Patients Hospitalized with COVID-19: Findings from the American Heart Association COVID-19 Cardiovascular Disease Registry. Presented by Fatima Rodriguez, M.D.

   • Association of Body Mass Index with Death, Mechanical Ventilation, and Cardiovascular Outcomes in COVID-19: Findings from the AHA COVID-19 Cardiovascular Disease Registry. Presented by Nicholas Hendren, M.D.

   • Impact of Cardiovascular Disease on Outcomes Among Hospitalized COVID-19 Patients: Results From >14,000 Patients Across the United States. Presented by Ann Marie Navar, M.D.

   • High Dose versus Standard Dose Influenza Vaccine in Patients With High Risk Cardiovascular Disease: Results From the INVESTED Trial. Presented by Orly Vardeny, M.D.

High Tech or High Touch: Creative Strategies to Optimize Patient Care

Tue, Nov. 17, Noon - 1 p.m. CST
   • Translating Guidelines into Practice, Presented by Mark D. Huffman, M.D.

   • An Electronically Delivered, Patient-activation Tool for Intensification of Medications for Chronic Heart Failure With Reduced Ejection Fraction: The EPIC-HF Trial. Presented by Larry A. Allen, M.D.

   • My Recorded On-demand Audio Discharge Instructions (MyRoad) in Heart Failure. Presented by Nancy M. Albert, M.D.

   • Digital Care Transformation: One-year Report Of >5,000 Patients Enrolled An A Remote Algorithm-based CV Risk Management Program To Achieve Optimal Lipid And Hypertension Control. Presented by Benjamin M. Scirica, M.D.

   • Group Medical Visits and Microfinance for Patients With Diabetes and Hypertension in Western Kenya: Results of the BIGPIC Trial. Presented by Rajesh Vedanthan, M.D.

 

Other AHA 2020 News:

VIDEO: Lingering Myocardial Involvement After COVID-19 Infection — Interview with Aaron Baggish, M.D.

New Novartis Data for Inclisiran Shows Effective and Sustained LDL-C Reduction at 17 Regardless of Age or Gender

VIDEO: Screening for Atrial Fibrillation Using Single Lead ECG in the VITAL-AF Trial

Links to all the American Heart Association 2019 Late-breaking Trials

TCT 2020 Late-breaking Study Presentations
 

Related Content

The American Heart Association (AHA) has cancelled its in-person annual meeting due to COVID-19 and plans to host a virtual, online meeting instead.

The American Heart Association (AHA) has cancelled its in-person annual meeting due to COVID-19 and plans to host a virtual, online meeting instead.

News | AHA | July 15, 2020
July 15, 2020 – The last major cardiovascular conference to go virtual in 2020 due to the...
cardiac arrest cath lab
News | AHA | November 21, 2019
November 21, 2019 — People who experience cardiac arr...
heart disease
News | AHA | November 20, 2019
November 20, 2019 — Heart attack survivors may have an increased risk of developing cancer compared to people without
 Assorted pastries
News | AHA | November 20, 2019
November 20, 2019 — Ultra-processed foods, which account for more than half of an average American’s daily calories,
marijuana leaf
News | AHA | November 20, 2019
November 20, 2019 — Frequent cannabis (marijuana) use among young people was linked to an increased risk of...
In the ISCHEMIA study, patients were randomized into one of two groups: a conservative strategy or an invasive strategy. Illustration by NYU Langone staff

In the ISCHEMIA study, patients were randomized into one of two groups: a conservative strategy or an invasive strategy. Illustration by NYU Langone staff 

Feature | AHA | November 19, 2019
November 19, 2019 — After 12 years of collecting data, the results of the landmark ISCHEMIA (International Study of C
The American Heart Association, AHA, 2019 meeting late breaking trials and key studies on cardiovascular science.
Feature | AHA | November 19, 2019 | Dave Fornell, Editor
Here is a list of the key late-breaking clinical study presentations at the 2019 American Heart Association (AHA)...
 doctor heart failure patient from CorAssist
News | AHA | November 14, 2019
November 14, 2019 — More than a million Americans face a doubling in their risk of death during or while recovering f